阿托伐他汀对老年人主要心血管事件及无残疾生存的影响
STAREE为澳大利亚全科诊所双盲随机安慰剂对照试验,纳入9971例≥70岁无心血管病、糖尿病或痴呆的社区居住成人,1:1接受阿托伐他汀40 mg每日一次或安慰剂。中位5.9年随访,主要心血管复合终点发生率阿托伐他汀组10.9/1000人年 vs 安慰剂组15.5/1000人年(HR 0.70;95%CI 0.61–0.82;P<0.001)。无残疾生存复合终点(全因死亡、痴呆或持续躯体残疾)两组无显著差异(HR 0.94;95%CI 0.84–1.05;P=0.25)。严重不良事件两组均为2.7%,肌肉骨骼、肝胆及糖尿病相关不良事件在阿托伐他汀组更常见。
要点
- 同一人群无残疾生存复合终点未获益(HR 0.94;95%CI 0.84–1.05;P=0.25),不能以延长无残疾生存为处他汀的理由。
- 严重不良事件发生率两组均为2.7%,但肌肉骨骼、肝胆、糖尿病相关不良事件在阿托伐他汀组更常见。
- 该试验仅适用于无临床心血管病的一级预防老人,不适用于已患心血管病或糖尿病者的二级预防决策。
- 急诊/ICU中不应据本试验启动他汀用于急性期无残疾生存改善,长期一级预防需结合个体风险与不良事件。
适用人群与场景
- 社区居住、年龄≥70岁、无心血管病、糖尿病或痴呆病史的成人,来自澳大利亚全科诊所。
- 不适用于已确诊心血管病、糖尿病或痴呆者,也不适用于急诊/ICU急性期常规启动他汀。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 阿托伐他汀40 mg口服每日一次,用于上述社区老人一级预防,中位疗程5.9年。
- 治疗期间需关注肌肉骨骼、肝胆及糖尿病相关不良事件,严重不良事件总发生率与安慰剂同为2.7%。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 双盲随机安慰剂对照试验,澳大利亚全科诊所,9971例(阿托伐他汀4984例、安慰剂4987例),平均年龄74.7±4.5岁,女性51.9%。
- 主要心血管复合终点(心血管死亡、非致死性心梗或卒中、冠脉血运重建):阿托伐他汀组297例(10.9/1000人年)vs 安慰剂组412例(15.5/1000人年),HR 0.70(95%CI 0.61–0.82;P<0.001)。
- 无残疾生存复合终点(全因死亡、痴呆或持续躯体残疾):阿托伐他汀组637例(21.6/1000人年)vs 安慰剂组676例(23.0/1000人年),HR 0.94(95%CI 0.84–1.05;P=0.25)。
- 严重不良事件:阿托伐他汀组131例(2.7%)vs 安慰剂组129例(2.7%);肌肉骨骼、肝胆及糖尿病相关不良事件在阿托伐他汀组更常见。
证据类型、等级与局限
- 证据类型:双盲随机安慰剂对照试验(RCT),由National Health and Medical Research Council等资助,注册号NCT02099123。
- 局限:仅纳入澳大利亚社区居住老人,不适用于已患心血管病或糖尿病者;原文未报告其他亚组或证据等级。
对床旁实践的改变
- 对≥70岁无心血管病、糖尿病、痴呆的社区老人,可考虑阿托伐他汀40 mg/d一级预防以减少主要心血管事件,但不应期望延长无残疾生存。
- 急诊/ICU急性期不依据本试验启动他汀;长期用药需权衡肌肉骨骼、肝胆及糖尿病相关不良事件,尤其在该人群。
- 不适用于已确诊心血管病或糖尿病者的二级预防决策;原文未提供急诊/ICU场景数据。
指南或共识出处
- STAREE试验(Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults),N Engl J Med,ClinicalTrials.gov NCT02099123。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effectiveness and safety of statins for the primary prevention of cardiovascular events and the extension of disability-free survival among older adults remain uncertain.
METHODS: We conducted a double-blind, randomized, placebo-controlled trial at general medical practices across Australia. Community-dwelling adults at least 70 years of age with no history of cardiovascular disease, diabetes, or dementia were randomly assigned in a 1:1 ratio to receive atorvastatin at a dose of 40 mg once daily or identical placebo. The two primary end points were a composite of death from cardiovascular causes, nonfatal myocardial infarction or stroke, or coronary revascularization (to assess effects on major cardiovascular events) and a composite of death from any cause, dementia, or persistent physical disability (to assess effects on disability-free survival). Analyses were performed according to a hierarchical testing plan.
RESULTS: A total of 9971 participants were enrolled: 4984 were assigned to receive atorvastatin and 4987 to receive placebo. The mean (±SD) age of the participants was 74.7±4.5 years, and 51.9% were women. After a median of 5.9 years, a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group (hazard ratio, 0.70; 95% confidence interval [CI], 0.61 to 0.82; P<0.001). Death from any cause, dementia, or persistent physical disability occurred in 637 participants (21.6 events per 1000 person-years) in the atorvastatin group and in 676 participants (23.0 events per 1000 person-years) in the placebo group (hazard ratio, 0.94; 95% CI, 0.84 to 1.05; P = 0.25). Serious adverse events occurred in 131 participants (2.7%) in the atorvastatin group and in 129 (2.7%) in the placebo group, with musculoskeletal, hepatobiliary, and diabetes-related adverse events occurring more commonly in the atorvastatin group.
CONCLUSIONS: Treatment with atorvastatin led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not result in longer disability-free survival among community-dwelling older adults without clinical cardiovascular disease. (Funded by the National Health and Medical Research Council and others; STAREE ClinicalTrials.gov number, NCT02099123.).
参考来源
- Zoungas S, Wolfe R, Moran C, et al. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. N Engl J Med. 2026. PMID: 42670961. doi:10.1056/NEJMoa2607314
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。